Kessler Investment Group LLC buys 3,631 shares of Pfizer Inc. (NYSE:PFE)


Kessler Investment Group LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating ) by 7.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,538 shares of the biopharmaceutical company’s stock after purchasing an additional 3,631 shares during the quarter. Pfizer makes up about 1.5% of Kessler Investment Group LLC’s portfolio, making the stock its 23rd largest position. Kessler Investment Group LLC’s holdings in Pfizer were worth $2,616,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in PFE. Norges Bank purchased a new position in Pfizer during the 4th quarter valued at $3,351,891,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in Pfizer by 577.8% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock valued at $715,270,000 after buying an additional 10,440,786 shares in the last quarter. Coatue Management LLC purchased a new position in Pfizer during the 4th quarter valued at $608,919,000. Darwin Global Management Ltd. purchased a new position in Pfizer during the 4th quarter valued at $454,553,000. Finally, State Street Corp boosted its stake in Pfizer by 1.8% in the 4th quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company’s stock valued at $16,818,434,000 after buying an additional 5,013,651 shares during the last quarter. Hedge funds and other institutional investors own 66.50% of the company’s shares.

In other Pfizer news, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $50.50, for a total transaction of $202,000.00. Following the completion of the transaction, the senior vice president now owns 15,064 shares of the company’s stock, valued at $760,732. The sale was disclosed in a legal filing with the Securities and Exchange Commission, which is available at this hyperlink. Also, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the transaction, the senior vice president now directly owns 10,846 shares of the company’s stock, valued at approximately $585,250.16. Disclosure of this sale can be found here. Insiders sold a total of 41,126 shares of company stock valued at $2,075,003 over the last ninety days. 0.05% of shares are currently owned by insiders.

Several research firms have weighed in on PFE. SVB Leerink started coverage on Pfizer in a research note on Monday, May 23rd. They set a “market perform” rating and a $55.00 target price on the stock. StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. Citigroup boosted their target price on Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research note on Tuesday, April 5th. Berenberg Bank set a $50.00 target price on Pfizer in a research note on Friday, May 27th. Finally, Morgan Stanley initiated coverage on Pfizer in a research note on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 target price on the stock. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Moderate Buy” and an average price target of $57.26, according to MarketBeat.

NYSE PFE opened at $52.31 on Monday. The stock has a market cap of $293.51 billion, a price-to-earnings ratio of 12.00, a PEG ratio of 0.64 and a beta of 0.73. Pfizer Inc. has a twelve month low of $38.93 and a twelve month high of $61.71. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average of $50.66 and a 200-day moving average of $52.03.

Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share for the quarter, missing analysts’ consensus estimates of $1.66 by ($0.04). The business had revenue of $25.66 billion during the quarter, compared to analyst estimates of $24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The business’s revenue for the quarter was up 76.8% compared to the same quarter last year. During the same period in the previous year, the company reported $0.93 EPS. Stock analysts predict that Pfizer Inc. will post 6.63 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Wednesday, June 29th will be given a $0.40 dividend. The ex-dividend date is Thursday, July 28th. This represents an annualized dividend of $1.60 and a yield of 3.06%. Pfizer’s payout ratio is 36.70%.

Pfizer Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products worldwide. Offers drugs and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin and Eliquis brands; biologics, small molecules, immunotherapies and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena and Braftovi brands; and sterile injectable and anti-infective drugs and oral treatments for COVID-19 under the brand names Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid.

Featured articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider deals for Pfizer Inc. (NYSE:PFE – Get Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)



Get Pfizer news and ratings daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.